Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density
The DOI matches its Crossref record.
Abstract
In a cross-sectional study of 39 patients with medullary thyroid carcinoma (MTC), we have investigated the effects of long-term calcitonin excess on bone mineral density. Bone mineral density was measured by dual X-ray absorptiometry at the lumbar spine between the second and fourth vertebra and by single photon absorptiometry at the distal forearm. The mean observation time of each patient between diagnosis of tumour and measurement of bone mineral density was 62·4 months (range 1–158 months). The mean calcitonin serum level was 14·4 μg/l at the time of measurement of bone mineral density. All patients were substituted with 150–200 μg l-thyroxine daily. At both sites, the mean bone mineral densities of all patients with MTC were not significantly different from controls. Patients with normal calcitonin levels (below 0·2 μg/l) after treatment had a normal bone mineral density of the spine but significantly (P <0·05) reduced bone mineral density values of the forearm. This was due to the decreased body surface areas of patients in this subgroup. Patients with multiple endocrine neoplasia type IIa had significantly higher bone mineral densities. Other bone-influencing factors, such as postoperative hypoparathyroidism, calcium intake, diarrhoea, menopause, tumour stage, previous anti-tumour treatment, or thyroxine substitution dose, did not affect bone mineral density. We thus conclude that long-term excess of endogenous calcitonin in patients with MTC has no positive effect on bone mineral density. Journal of Endocrinology (1992) 134, 141–147
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcium metabolism and bone mineral density are unaffected in patients with medullary thyroid carcinoma who have long-term excess of endogenous calcitonin levels, or in patients who had undergone thyroidectomy and have undetectable circulating calcitonin (105, 223).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [223]
In the citing paper
“Although neither the absence nor pathologically high levels of endogenous calcitonin appear to affect bone mass, pharmacological use of calcitonin was considered a promising option for the inhibition of bone turnover, preservation of bone mass, and fracture prevention (105, 223).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [223]
Citations
Cites
Still being checked.
Cited by
Gastric Acid, Calcium Absorption, and Their Impact on Bone Health
Kopic, S., & Geibel, J. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00015.2012 · Cited by 176
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
Hip fractures and the thyroid: a case‐control study
Wejda, B., Hintze, G., Katschinski, B., Olbricht, T., & Benker, G. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01172.x · Cited by 83
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. A., & Sun, Q. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3236828 · Cited by 83
Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential
Meshcheryakova, A., Mechtcheriakova, D., & Pietschmann, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1332180 · Cited by 74
Metadata
- Authors
- Wüster, C., Raue, F., Meyer, C., Bergmann, M., & Ziegler, R.
- Affiliations
- Heidelberg University (DE)
- ORCID
- Raue, F.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1992-07-01
- Volume
- 134
- Issue
- 1
- Pages
- 141-147
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2049133343
- Cited by
- 20
- References
- 0
- Citations by year
- 2026: 2 · 2024: 2 · 2022: 1 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 3 · 2013: 1 · 2012: 1
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- medullary thyroid carcinoma, calcitonin, bone mineral density, multiple endocrine neoplasia type IIa, hypoparathyroidism, forearm bones, body surface area, bone metabolism
- MeSH terms
- Adult, Calcitonin, Carcinoma, Cross-Sectional Studies, Female, Humans, Male, Menopause, Middle Aged, Multiple Endocrine Neoplasia, Thyroid Neoplasms, Time Factors, Absorptiometry, Photon, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. https://app.cochat.ai/papers/10.1677/joe.0.1340141
- The paper
- Wüster, C., Raue, F., Meyer, C., Bergmann, M., & Ziegler, R. (1992). Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. Journal of Endocrinology. https://doi.org/10.1677/joe.0.1340141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.